| 前收市價 | 5.50 |
| 開市 | 5.50 |
| 買盤 | 6.85 |
| 賣出價 | 7.05 |
| 拍板 | 100.00 |
| 到期日 | 2023-03-17 |
| 今日波幅 | 5.50 - 6.80 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 4.68k |
- AASTOCKS
《大行報告》高盛上調默沙東(MRK.US)目標價至120美元 評級「買入」
高盛發表研究報告指，默沙東(MRK.US)日前公布去年第四季業績，績後股價表現跑輸大市，認為是一個較吸引的買入機會，目標價由118美元上調至120美元。 該行指出，癌症免疫療法單抗Keytruda的銷售額略低於該行及市場預期，但該產品近日於非小細胞肺癌(NSCLC)輔助治療方面獲批，管理層預期增長將會循序漸進。 高盛又指，默沙東對疫苗業務的前景持積極態度，在產能提升下Gardasil(子宮頸癌疫苗)今年增長速度將加快。憧憬即將舉行的美國心臟病學學院(ACC)會議上分享的重要臨床數據、已商業化產品持續釋放潛力，以及公司過往的穩健財政能力，將繼續帶來增長動力，同時預期默沙東在業務發展及併購方面的資本配置戰略，將為股東帶來價值，預測今年將進行約40億美元的回購，重申「買入」評級並列入確信買入名單。(gc/u)~ 阿思達克財經新聞 網址: www.aastocks.com
- Insider Monkey
12 Safe Stocks to Buy For Long-Term
In this article, we take a look at 12 safe stocks to buy for the long-term according to hedge funds. You can skip our detailed analysis of safe stocks and go directly to read 5 Safe Stocks to Buy According to Hedge Funds. Even if there are many indications that the macro environment will remain […]
- Benzinga
Merck's Keytruda Plus Chemo Combo Aces Late-Stage Study In Advanced Endometrial Cancer Patients
Merck & Co Inc's (NYSE: MRK) Phase 3 NRG-GY018 trial evaluating Keytruda (pembrolizumab) combined with standard-of-care chemotherapy (carboplatin and paclitaxel) met its primary endpoint of progression-free survival (PFS). The trial covered patients with stage III-IV or recurrent endometrial carcinoma regardless of mismatch repair status. Related: Merck's Keytruda Phase 3 Trial Meets Primary Endpoint In Gastric Cancer Patients. The treatment regime included Keytruda + Chemo combo, then continued
